Topline Six-Month Results From Phase IIb Study of Avicursen
Filed with ASX · · 3 pages · English
Summary by 6ix AI
Percheron Therapeutics Limited has announced the topline six-month results from its Phase IIb study of avicursen in non-ambulant boys with Duchenne muscular dystrophy. The trial did not meet its primary endpoint, showing no statistically significant differences in efficacy compared to placebo. The company has decided to terminate the study due to these results and will conduct a strategic review of the avicursen program in the coming months. The drug was reported to be safe and well-tolerated, with mild to moderate injection site reactions being the most common adverse event.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Percheron Therapeutics Limited on 6ix
Story so far
Earlier from Percheron Therapeutics
- Clinical Trial Update
- Results of Share Purchase Plan
- Percheron to launch Share Purchase Plan
- $13.0 million Institutional Placement
- Completion of avicursen (ATL1102) toxicology study
Later from Percheron Therapeutics
- Letter From The Chair and Half Year Accounts
- Response to ASX Query
- Trading Halt
- Percheron licenses HMBD-002 from Hummingbird Bioscience
- Appendix 4E and Annual Report
Follow Percheron Therapeutics into a list and get an email when it puts out news.
Follow Percheron Therapeutics